Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z4UN
|
|||
| Former ID |
DAP000594
|
|||
| Drug Name |
Pimecrolimus
|
|||
| Synonyms |
Elidel; ASM 981; SDZ ASM 981; ASM-981; ASM-998; Elidel (TN); SDZ-ASM 981; Pimecrolimus [USAN:INN:BAN]; SDZ-ASM-981; Pimecrolimus (JAN/USAN/INN); 33-epi-Chloro-33-desoxyascomycin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Approved | [1], [2] | |
| Therapeutic Class |
Dermatologic Agents
|
|||
| Company |
Norvatis Phamaceuticals Corporation
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C43H68ClNO11
|
|||
| Canonical SMILES |
CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)Cl)C)O)C)OC)OC)C)C
|
|||
| InChI |
1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
|
|||
| InChIKey |
KASDHRXLYQOAKZ-XDSKOBMDSA-N
|
|||
| CAS Number |
CAS 137071-32-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
11624458, 12014634, 14767061, 14791428, 47207149, 50112759, 57370850, 76102367, 90342402, 91011860, 99436941, 103770669, 124757871, 125164674, 126592929, 142127478, 152035365, 152344331, 162037995, 162202449, 163395064, 175266451, 178103389, 210274942, 210280580, 224029253, 226761846, 229056493, 241033484, 243025934, 249867997, 251883501, 252070159, 252819805
|
|||
| ChEBI ID |
CHEBI:135888
|
|||
| ADReCS Drug ID | BADD_D01773 | |||
| SuperDrug ATC ID |
D11AH02
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6783). | |||
| REF 2 | Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52. | |||
| REF 3 | Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.